Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Prostatic Neoplasms 2Glioma 2Glioblastoma 2Weight Loss 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Splenomegaly 1Sarcoma, Kaposi 1Oligodendroglioma 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1HIV Infections 1Gliosarcoma 1Fever 1Fatigue 1Ependymoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Ritonavir × Clear all
NCT02770378 2021-10-05

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

University of Ulm

Phase 1/2 Completed
10 enrolled
CNS

Glioblastoma

NCT01095094 2013-06-10

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Case Comprehensive Cancer Center

Phase 2 Terminated
19 enrolled 9 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡